These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 31057108)
21. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
22. A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. Demirtaş M; Falcon C; Tucholka A; Gispert JD; Molinuevo JL; Deco G Neuroimage Clin; 2017; 16():343-354. PubMed ID: 28861336 [TBL] [Abstract][Full Text] [Related]
23. Connected speech and language in mild cognitive impairment and Alzheimer's disease: A review of picture description tasks. Mueller KD; Hermann B; Mecollari J; Turkstra LS J Clin Exp Neuropsychol; 2018 Nov; 40(9):917-939. PubMed ID: 29669461 [TBL] [Abstract][Full Text] [Related]
24. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236 [TBL] [Abstract][Full Text] [Related]
25. Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. Skouras S; Falcon C; Tucholka A; Rami L; Sanchez-Valle R; Lladó A; Gispert JD; Molinuevo JL Neuroimage Clin; 2019; 22():101777. PubMed ID: 30913531 [TBL] [Abstract][Full Text] [Related]
26. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806 [TBL] [Abstract][Full Text] [Related]
27. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O; Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649 [TBL] [Abstract][Full Text] [Related]
28. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]
29. Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer's disease. Mirandez RM; Aprahamian I; Talib LL; Forlenza OV; Radanovic M Int Psychogeriatr; 2017 Jun; 29(6):949-958. PubMed ID: 28179036 [TBL] [Abstract][Full Text] [Related]
30. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
31. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653 [TBL] [Abstract][Full Text] [Related]
32. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample. Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924 [TBL] [Abstract][Full Text] [Related]
33. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Risacher SL; Saykin AJ Annu Rev Clin Psychol; 2013; 9():621-48. PubMed ID: 23297785 [TBL] [Abstract][Full Text] [Related]
34. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]